UTR Therapeutics Inc Announces IND Submission to the US FDA for a First-in-Human Clinical Trial of an mRNA Destabilizing Drug Targeting c-MYC Driven Cancers

UTR Therapeutics Inc. announced a new milestone, the submission of an Investigational New Drug (IND) application to the US FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers.